OTLK ▲ +1.8% - Outlook Therapeutics, Inc.
$OTLK OTLKW - Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
01-OCT-2026 09:01 AM ET
Share this post
More filings for $OTLK
OTLK ▲ +1.5% - Outlook Therapeutics, Inc.Sep 11, 2026OTLK ▲ +3.2% - Outlook Therapeutics, Inc.Aug 27, 2026OTLK ▲ +1.6% - Outlook Therapeutics, Inc.Aug 27, 2026OTLK - Outlook Therapeutics, Inc. - SEC Filing Update (19-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 19, 2026OTLK - Outlook Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 15, 2026
View full $OTLK filing history →💬 Comments
Loading comments…
Leave a comment